SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for RLAY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 50.06M
March 31, 2026 49.00M
December 31, 2025 56.71M
September 30, 2025 61.40M
June 30, 2025 69.02M
March 31, 2025 75.53M
December 31, 2024 76.59M
September 30, 2024 76.45M
June 30, 2024 75.19M
March 31, 2024 75.17M
December 31, 2023 74.95M
September 30, 2023 74.56M
June 30, 2023 72.14M
March 31, 2023 69.49M
December 31, 2022 65.98M
Date Value
September 30, 2022 65.15M
June 30, 2022 63.76M
March 31, 2022 60.72M
December 31, 2021 57.39M
September 30, 2021 57.38M
June 30, 2021 54.93M
March 31, 2021 46.56M
December 31, 2020 38.58M
September 30, 2020 26.47M
June 30, 2020 17.89M
March 31, 2020 15.34M
December 31, 2019 13.65M
September 30, 2019 10.23M
June 30, 2019 6.575M
March 31, 2019 3.067M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
AbbVie, Inc. 14.67B
TG Therapeutics, Inc. 296.46M
Karyopharm Therapeutics, Inc. 101.98M
Krystal Biotech, Inc. 159.89M
Akebia Therapeutics, Inc. 117.15M